Equities

Pasithea Therapeutics Corp

KTTA:NAQ

Pasithea Therapeutics Corp

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)4.42
  • Today's Change-0.38 / -7.92%
  • Shares traded9.40k
  • 1 Year change-53.08%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.

  • Revenue in USD (TTM)0.00
  • Net income in USD-16.37m
  • Incorporated2020
  • Employees8.00
  • Location
    Pasithea Therapeutics Corp1111 Lincoln RoadMIAMI BEACH 33139United StatesUSA
  • Phone+1 (786) 977-3380
  • Websitehttps://www.pasithea.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Galera Therapeutics Inc0.00-29.11m4.30m7.00---------0.5892-0.58920.00-2.540.00----0.00-90.03-83.69-119.01-97.54-----------14.3411.60------5.05---29.84--
Notable Labs Ltd313.00k-16.74m4.34m16.00--0.6037--13.86-2.47-2.470.0460.74390.0176----19,562.50-93.89-52.02-120.26-62.0937.7060.19-5,346.97-3,636.93----0.0405---52.89-11.9365.13---50.69--
Synaptogenix Inc0.00-3.45m4.39m5.00--0.2229-----3.89-3.890.0014.990.00----0.00-5.54-40.33-6.89-43.36------------0.00-------142.17---3.21--
Alaunos Therapeutics Inc7.00k-19.13m4.42m1.00--1.17--631.35-11.95-11.950.00442.360.0004--1.757,000.00-117.34-74.83-143.58-89.57-----273,271.40-10,508.06----0.00---99.83-49.086.86---15.56--
Palisade Bio Inc0.00-14.17m4.45m9.00--0.3653-----20.07-20.070.0010.300.00----0.00-90.97-132.36-109.07-165.45-------27,892.32---972.730.0339-----0.781413.74--18.53--
Oncternal Therapeutics Inc1.85m-35.97m4.53m27.00--0.2875--2.45-12.19-12.190.62545.320.0495----68,370.37-96.40-49.40-116.52-54.51-----1,948.70-1,342.98----0.00---47.32--10.62------
Qualigen Therapeutics Inc0.00-9.27m4.57m4.00---------1.66-1.750.00-0.4450.00----0.00-134.64-----------------9.64--------10.22------
CNS Pharmaceuticals Inc0.00-15.97m4.60m3.00---------134.04-134.040.00-2.970.00----0.00-358.12-132.47---185.75---------------------23.42------
Pasithea Therapeutics Corp0.00-16.37m4.61m8.00--0.2853-----14.98-14.990.0015.490.00----0.00-58.66---62.74--------------0.00-------32.23------
Chromocell Therapeutics Corp0.00-8.98m4.90m4.00--4.34-----1.66-1.660.000.1960.00----0.00-440.01-----------------7.200.00-------200.20------
ProtoKinetix, Inc.0.00-369.97k4.91m0.00--12.10-----0.0011-0.00110.000.00120.00-------78.67-696.88-85.20-785.51------------0.00------78.22--10.78--
Clearmind Medicine Inc0.00-8.44m4.91m----1.39-----12.73-12.730.000.87280.00-------133.31-218.20-266.82-488.96-----------2.600.0172-------25.03------
Cingulate Inc0.00-19.10m4.94m13.00--1.32-----141.60-141.600.003.950.00----0.00-368.85-----------------47.380.0042-------33.14------
Data as of Sep 20 2024. Currency figures normalised to Pasithea Therapeutics Corp's reporting currency: US Dollar USD

Institutional shareholders

2.87%Per cent of shares held by top holders
HolderShares% Held
Adar1 Capital Management LLCas of 30 Jun 202427.70k2.65%
Tower Research Capital LLCas of 30 Jun 20241.81k0.17%
RBC Dominion Securities, Inc. (Investment Management)as of 30 Jun 2024250.000.02%
JPMorgan Securities LLC (Investment Management)as of 30 Jun 2024150.000.01%
Strategic Advisers LLCas of 30 Jun 202449.000.01%
UBS Securities LLCas of 30 Jun 202438.000.00%
Bank of America, NA (Private Banking)as of 30 Jun 20246.000.00%
Wells Fargo Bank, NA (Private Banking)as of 30 Jun 20240.000.00%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.